skip to content

Cambridge Cardiovascular

 

Research

DR ANA-MISHEL SPIROSKI HAS LEFT CAMBRIDGE AND IS NOW A POSTDOCTORAL RESEARCH FELLOW AT THE UNIVERSITY OF EDINBURGH.

Experimental medical interventions for cardiometabolic disease

Pathological conditions resulting in ischaemia reduce oxygen and nutrient delivery to the effected tissues. In conditions such as cerebral or myocardial infarct, despite acute tissue-specific adaptations to maintain function in the face of deprivation, tissue death can occur. However, in instances of chronic ischaemia, such as that found in the growth-restricted fetus, developmental plasticity and fetal adaptation to in utero adversity promotes immediate survival, but at the expense of cardiorespiratory development and metabolic competence. Dr Spiroski’s work focuses on experimental interventions to improve outcomes in acute ischaemic injury, such as during a heart attack or stroke, and in offspring of complicated pregnancy, who are predisposed to the early development of cardiometabolic disease. The most appropriate pharmacological approach in order to improve clinical outcomes is not only time-dependent, but pertinent to both the nature of the ischaemic injury, and to the programmed physiological adaptations with which the individual lives. Dr Spiroski’s translational expertise integrates interdisciplinary methods, from molecular biology to systems physiology, to investigate novel interventions to improve outcomes following ischaemic events.

Publications

Key publications: 

Intrauterine Intervention for the Treatment of Fetal Growth Restriction. Spiroski AM, Oliver MH, Harding JE, Bloomfield FH. Curr Pediatr Rev. 2016;12(3):168-178.

Fetal growth factors and fetal nutrition. Bloomfield FH, Spiroski AM, Harding JE. Semin Fetal Neonatal Med. 2013 Apr 30. pii: S1744-165X(13)00022-X.

ORCID list  https://orcid.org/0000-0002-8584-8048